OxVax Company

OxVax focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
Technology: Dendritic Cells
Industry: Dendritic Cells
Headquarters: Oxford, Oxfordshire, United Kingdom
Founded Date: 2021-01-01
Funding Status: Seed
Investors Number: 2
Total Funding: 12500000
Last Funding Date: 2021-04-21
Last Funding Type: Seed

Visit Website
info@oxvax.uk
https://www.twitter.com/scancellpharma
Register and Claim Ownership